CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

CAMP4 Therapeutics (Nasdaq: CAMP) announced an inducement equity award granted on January 15, 2026 under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee granted a non-qualified stock option for 8,000 shares to a newly hired employee with a 10-year term and an exercise price of $5.78 per share (closing price on the grant date). The option vests over four years: 25% at the one-year anniversary, then monthly over 36 months, subject to continued service, and is governed by an Inducement Option Award Agreement.

News Market Reaction – CAMP

-21.00%

1 alert

-21.00% News Effect

On the day this news was published, CAMP declined 21.00%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement option size: 8,000 shares Option exercise price: $5.78 per share Option term: 10 years +5 more

8 metrics

Inducement option size 8,000 shares Non-qualified stock option granted Jan 15, 2026 to a new employee

Option exercise price $5.78 per share Equal to CAMP’s closing price on the Jan 15, 2026 grant date

Option term 10 years Term of the inducement non-qualified stock option

Vesting schedule 25% at 1 year; 36 monthly installments Four-year vesting subject to continued service

Shelf registration capacity $300,000,000 Form S-3 universal shelf filed Nov 10, 2025

ATM program size $100,000,000 At-the-market common stock program under the S-3 shelf

Underwritten offering $30.0 million gross 5,000,000 shares at $6.00 per share priced Dec 18, 2025

GSK upfront payment $17.5 million Upfront from GSK collaboration signed Dec 18, 2025

Market Reality Check

Price: $5.38 Vol: Volume 54,268 is about 22...

low vol

$5.38 Last Close

Volume Volume 54,268 is about 22% of the 20-day average (251,691), indicating muted trading ahead of this filing. low

Technical Shares at $5.78 are trading above the 200-day MA of $2.87 and about 20.9% below the 52-week high of $7.305.

Peers on Argus

While CAMP fell 2.36%, close peers showed mixed moves: CUE (-17.07%), DTIL (-6.0...

While CAMP fell 2.36%, close peers showed mixed moves: CUE (-17.07%), DTIL (-6.02%), PDSB (-3.64%), versus PYPD (+3.55%) and ADVM (+2.83%). This pattern points to stock-specific trading rather than a uniform biotech sector rotation.

Historical Context

5 past events · Latest: Jan 06 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 06	Conference presentation	Neutral	+0.0%	Announcement of corporate presentation at JPM healthcare conference with webcast access.
Dec 18	Equity offering	Negative	-12.9%	Pricing of $30M underwritten common stock offering at $6.00 per share.
Dec 18	Strategic collaboration	Positive	-12.9%	Research and license agreement with GSK including $17.5M upfront and milestones.
Dec 12	Inducement grants	Neutral	+4.0%	Inducement stock options totaling 92,000 shares for four new employees.
Nov 14	Inducement grant	Neutral	-2.7%	Inducement option for 80,000 shares to a new hire with four-year vesting.

Pattern Detected

Recent history shows capital-raising and collaboration news drawing negative reactions, while routine inducement grants and conference updates have seen modest or flat moves, indicating investors focus more on financing terms and dilution than on administrative equity awards.

Recent Company History

Over the past few months CAMP4 has balanced financing, partnerships, and routine corporate updates. On Dec 18, 2025, a $30.0 million underwritten offering and a strategic collaboration with GSK both preceded a -12.9% move, suggesting sensitivity to dilution even alongside positive partnering news. Earlier inducement option grants on Nov 12 and Dec 11, 2025 featured similar four-year vesting and market-priced options, with modest price reactions. The current 8,000-share inducement option continues this pattern of small, employment-related equity awards.

Regulatory & Risk Context

Active S-3 Shelf · $300,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-10

$300,000,000 registered capacity

An effective Form S-3 shelf filed on Nov 10, 2025 registers up to $300,000,000 of securities and includes an at-the-market program for up to $100,000,000 of common stock through Leerink Partners, providing substantial future financing flexibility and potential dilution capacity.

Market Pulse Summary

The stock dropped -21.0% in the session following this news. A negative reaction despite the routine...

Analysis

The stock dropped -21.0% in the session following this news. A negative reaction despite the routine nature of this inducement grant would fit a pattern where investors closely scrutinize equity issuance and dilution. The option, covering 8,000 shares at $5.78, is small relative to prior financings such as the $30.0 million offering, yet it adds incrementally to outstanding equity. Combined with the company’s $300,000,000 shelf and $100,000,000 ATM capacity, sentiment could remain sensitive to any additional stock-based actions.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock option, exercise price

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock option financial

"granted a non-qualified stock option to purchase 8,000 shares of the Company’s common stock"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

exercise price financial

"an exercise price per share of $5.78, which is equal to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on January 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

The Inducement Grant has a ten-year term and an exercise price per share of $5.78, which is equal to the closing price of CAMP4’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments, subject to the employee’s continued service with CAMP4 through the applicable vesting dates. The Inducement Grant was granted pursuant to, and is subject to, the terms and conditions of an Inducement Option Award Agreement.

About CAMP4 Therapeutics 
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform^® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.

Contacts

Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com

Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com

FAQ

What did CAMP4 (CAMP) grant on January 15, 2026?

CAMP4 granted a non-qualified stock option for 8,000 shares to a newly hired employee as an inducement under Nasdaq Rule 5635(c)(4).

What is the exercise price and term of the CAMP4 inducement option (CAMP)?

The option has a $5.78 exercise price per share and a 10-year term, matching the closing price on the grant date.

How does the CAMP4 (CAMP) inducement option vest?

The option vests over four years: 25% on the one-year anniversary of employment, then the remainder in 36 equal monthly installments, subject to continued service.

Which Nasdaq rule governed CAMP4's inducement grant (CAMP)?

The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4), which covers inducement equity awards for new employees.

Is the CAMP4 inducement option subject to additional terms?

Yes; the option is subject to the terms and conditions of an Inducement Option Award Agreement between the company and the employee.